BioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA
BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced positive preliminary data from preclinical studies evaluating BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. Thus far, in the preclinical studies, the product is successfully delivering above adequate sustained release levels of naltrexone. The study has so far confirmed a number of the expected advantages of BICX101.The Company is also expecting Innovative Science Solutions...
View full press release